Light‑Activated Switch Forces Dormant Lung Cancer Cells to Re‑Enter Growth Cycle

Light‑controlled wake‑up call for dormant cells

Researchers at ETH Zurich reported on Monday that a light‑controlled molecular switch can rouse dormant lung‑cancer cells, making them vulnerable to chemotherapy. The study, published in Nature Cancer , used blue‑light pulses on cultured tumor cells and mouse models to trigger cell‑cycle genes that had been silenced during dormancy.

Tumor cells often slip into a quiescent state to survive drug treatment, a phenomenon linked to cancer relapse. The Zurich team engineered a light‑sensitive protein that binds DNA only when illuminated, activating genes that drive cell division. In laboratory experiments, a brief exposure to blue light awakened up to 85 % of dormant cells, which then succumbed to standard chemotherapy within 48 hours. Mouse models showed a similar pattern: tumors with dormant pockets shrank dramatically after combined light exposure and drug therapy.

The researchers built on optogenetic tools originally developed for neuroscience. By fusing a blue‑light receptor to a transcriptional activator, they created a switch that remains off until illuminated. „We wanted a precise, non‑chemical trigger to coax cells out of hiding,” said lead author Dr Lena Müller. Experiments revealed that a ten‑second light pulse was enough to restart the cell‑cycle engine. Subsequent drug treatment reduced viable tumor cells by more than three‑fold compared with chemotherapy alone. The approach proved effective across several lung‑cancer cell lines, suggesting a broad applicability.

Can shining light improve lung‑cancer outcomes?

While the concept is promising, translating it to patients poses challenges. Delivering sufficient light deep inside the lung tissue requires fiber‑optic probes or specialized endoscopic devices. The team is already testing minimally invasive catheters that emit controlled light pulses during bronchoscopy. Early safety tests in animals showed no tissue damage from the light doses used. „If we can integrate this with existing diagnostic procedures, we could target dormant cells without additional surgeries,” noted senior researcher Prof Markus Keller.

The discovery opens a new avenue for tackling cancer persistence. By forcing dormant cells to re‑enter the proliferative phase, clinicians could eradicate the hidden reservoirs that often cause relapse. Future trials will assess optimal light schedules, drug combinations, and long‑term outcomes. If successful, light‑driven awakening could become a standard adjunct to chemotherapy for lung cancer and perhaps other solid tumors.

Frequently Asked Questions

How does the light switch work? A blue‑light‑sensitive protein binds DNA only when illuminated, turning on genes that push dormant cells back into division.

Is the technique safe for patients? Animal studies show no damage from the brief light pulses, and the planned delivery methods use existing bronchoscopic tools.

Will this replace chemotherapy? No. The light switch is intended to complement chemotherapy, making dormant cells susceptible to drugs that would otherwise miss them.